Skip to Main Content

An official website of the United States government

About this Publication
Title
A prospective study of circulating adipokine levels and risk of multiple myeloma.
Pubmed ID
23007407 (View this publication on the PubMed website)
Publication
Blood. 2012 Nov; Volume 120 (Issue 22): Pages 4418-20
Authors
Hofmann JN, Liao LM, Pollak MN, Wang Y, Pfeiffer RM, Baris D, Andreotti G, Lan Q, Landgren O, Rothman N, Purdue MP
Affiliations
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892-7240, USA. hofmannjn@mail.nih.gov
Abstract

It has been hypothesized that the observed excess risk of multiple myeloma (MM) among obese persons could be the result of altered circulating levels of adipokines, polypeptide hormones with pro- and anti-inflammatory properties secreted by adipose tissue. We investigated whether circulating levels of leptin, total adiponectin, and high molecular weight adiponectin are associated with subsequent MM risk among 174 MM patients and 348 controls within the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Inverse associations with MM were observed for total adiponectin (highest quartile vs lowest: odds ratio = 0.49; 95% CI = 0.26-0.93, P(trend) = .03) and high molecular weight adiponectin (0.44; 0.23-0.85, P(trend) = .01). These associations remained after restricting to MM patients diagnosed ∼ 8 years or more after blood collection. Leptin levels were not associated with MM risk. The results of this study, to our knowledge the first prospective investigation of circulating adipokines and MM, suggest that adiponectin may play an important role in obesity-related myelomagenesis.

Related CDAS Studies
Related CDAS Projects